Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

2020; Massachusetts Medical Society; Volume: 383; Issue: 18 Linguagem: Inglês

10.1056/nejmoa2027071

ISSN

1533-4406

Autores

Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst,

Tópico(s)

Gastric Cancer Management and Outcomes

Resumo

Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.

Referência(s)